FrancophonIA/ELRC3.0 huggingface dataset:
English: Entresto is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (Child-Pugh C classification) (see section 4.3).
Danish: Entresto er kontraindiceret hos patienter med svært nedsat leverfunktion, biliær cirrhose eller cholestase (Child-Pugh klasse C) (se pkt.
English: Approximate tablet dimensions 13.1 mm x 5.2 mm. Entresto 49 mg/51 mg film-coated tablets
Danish: Tabletdimensioner er ca. 13,1 mm x 5,2 mm. Entresto 49 mg/51 mg filmovertrukne tabletter
English: 14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 196 film-coated tablets
Danish: 14 filmovertrukne tabletter 20 filmovertrukne tabletter 28 filmovertrukne tabletter 56 filmovertrukne tabletter 196 filmovertrukne tabletter
English: Entresto 97 mg/103 mg film-coated tablets
Danish: Entresto 97 mg/103 mg filmovertrukne tabletter
English: If any of the above applies to you, tell your doctor or pharmacist before you take Entresto.
Danish: Hvis noget af ovenstående passer på dig, skal du tale med din læge eller apotekspersonalet før du tager Entresto.
English: If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Entresto (see “Other medicines and Entresto”).
Danish: Hvis du har taget en ACE-hæmmer, skal du vente i 36 timer efter at have taget den sidste dosis, før du begynder at tage Entresto (se ”Brug af anden medicin sammen med Entresto”).
English: Entresto 24 mg/26 mg film-coated tablets
Danish: Entresto 24 mg/26 mg filmovertrukne tabletter
English: Entresto 49 mg/51 mg film-coated tablets
Danish: Entresto 49 mg/51 mg filmovertrukne tabletter
English: Pack sizes: 14, 20, 28, 56, 168 or 196 film-coated tablets and multipacks containing 168 (3x56) or 196 (7x28) film-coated tablets.
Danish: Pakningsstørrelser: 14, 20, 28, 56, 168 eller 196 filmovertrukne tabletter og multipakninger indeholdende 168 (3x56) eller 196 (7x28) filmovertrukne tabletter.
English: Approximate tablet dimensions 13.1 mm x 5.2 mm. Entresto 97 mg/103 mg film-coated tablets
Danish: Tabletdimensioner er ca. 13,1 mm x 5,2 mm. Entresto 97 mg/103 mg filmovertrukne tabletter
English: It is teratogenic based on a low incidence of foetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at an Entresto dose of ≥4.9 mg sacubitril/5.1 mg valsartan/kg/day.
Danish: Med baggrund i en lille forekomst af føtal hydrocephali relateret til maternelle toksiske doser, som sås hos kaniner ved en Entrestodosis ≥4,9 mg sacubitril/5,1 mg valsartan/kg/dag, er
English: Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets
Danish: Entresto 24 mg/26 mg filmovertrukne tabletter Entresto 49 mg/51 mg filmovertrukne tabletter Entresto 97 mg/103 mg filmovertrukne tabletter
English: Entresto 49 mg/51 mg film-coated tablets are pale yellow oval tablets with “NVR” on one side and “L1” on the other side.
Danish: Entresto 49 mg/51 mg filmovertrukne tabletter er svagt gule ovale tabletter med ”NVR” på den ene side og ”L1” på den anden side.
English: The combination of Entresto with direct renin inhibitors such as aliskiren is not recommended (see section 4.4).
Danish: Kombination af Entresto med direkte reninhæmmere som fx aliskiren frarådes (se pkt.
English: If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take Entresto (see “Do not take Entresto”).
Danish: Hvis du har taget en ACEhæmmer, skal du vente i 36 timer efter at have taget den sidste dosis ACE-hæmmer, før du kan starte med at tage Entresto (se ”Tag ikke Entresto”).
English: ≥49 mg sacubitril/51 mg valsartan/kg/day (≤0.72-fold the maximum recommended human dose [MRHD] on the basis of AUC) and rabbits at doses ≥4.9 mg sacubitril/5.1 mg valsartan/kg/day (2-fold and 0.03-fold the MRHD on the basis of valsartan and LBQ657 AUC, respectively).
Danish: Behandling med Entresto under organdannelsen resulterede i øget embryoføtal dødelighed hos rotter ved doser ≥49 mg sacubitril/51 mg valsartan/kg/dag (≤0,72 gange den maksimalt anbefalede dosis til mennesker [MRHD] vurderet ud fra AUC) og kaniner ved doser ≥4,9 mg sacubitril/5,1 mg valsartan/kg/dag (henholdsvis 2 gange og 0,03 gange MHRD vurderet ud fra AUC for valsartan og LBQ657).
English: Pack sizes: 14, 20, 28, 56 or 196 film-coated tablets and multipacks containing 196 (7x28) film-coated tablets.
Danish: Pakningsstørrelser: 14, 20, 28, 56 eller 196 filmovertrukne tabletter og multipakninger indeholdende 196 (7x28) filmovertrukne tabletter.
English: Cases of symptomatic hypotension have been reported in patients treated with Entresto during clinical studies (see section 4.8), especially in patients ≥65 years old, patients with renal disease and patients with low SBP (<112 mmHg).
Danish: 4.8), især hos patienter ≥65 år, patienter med nyresygdom og patienter med lavt SBT (<112 mmHg.).
English: Entresto must not be started until 36 hours after taking the last dose of ACE inhibitor therapy.
Danish: Entresto må ikke påbegyndes før 36 timer efter indtagelse af den sidste dosis ACE-hæmmer.
English: Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Danish: Entresto 24 mg/26 mg filmovertrukne tabletter Entresto 49 mg/51 mg filmovertrukne tabletter Entresto 97 mg/103 mg filmovertrukne tabletter sacubitril/valsartan
English: Additionally, in a toxicology study in cynomolgus monkeys treated with Entresto at 146 mg sacubitril/154 mg valsartan/kg/day for 39 weeks, there was no evidence for the presence of amyloid plaques in the brain.
Danish: Ydermere var der ingen tegn på forekomst af amyloid plaques i hjernen hos cynomolgus aber, der blev behandlet med Entresto 146 mg sacubitril/154 mg valsartan/kg/dag i 39 uger i et toksikologisk studie.
English: If treatment with Entresto is stopped, ACE inhibitor therapy must not be initiated until 36 hours after the last dose of Entresto (see sections 4.2, 4.3 and 4.5).
Danish: Hvis behandling med Entresto afbrydes, må behandling med ACEhæmmer ikke påbegyndes før 36 timer efter sidste dosis Entresto (se pkt.
English: • Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see sections 4.2 and 4.5).
Danish: • Entresto indeholder valsartan og må derfor ikke gives sammen med et andet produkt indeholdende en ARB.
English: How to store Entresto
Danish: Sådan skal du tage Entresto
English: Sodium and/or volume depletion should be corrected before starting treatment with Entresto, however, such corrective action must be carefully weighed against the risk of volume overload.
Danish: Hyponatriæmi og/eller hypovolæmi bør korrigeres før behandling med Entresto påbegyndes.
English: What Entresto looks like and contents of the pack Entresto 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Danish: Entresto 24 mg/26 mg filmovertrukne tabletter er violet-hvide ovale tabletter med ”NVR” på den ene side og ”LZ” på den anden side.
English: The concomitant use of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see section 4.3).
Danish: Anvendelse af Entresto sammen med produkter indeholdende aliskiren er kontraindiceret hos patienter med diabetes mellitus eller hos patienter med nedsat nyrefunktion (eGFR <60 ml/min/1,73 m2) (se pkt.
English: Entresto must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
Danish: Entresto må ikke indgives før 36 timer efter behandling med ACE-hæmmer er afbrudt.
English: • The combination of Entresto with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3).
Danish: • På grund af en øget risiko for angioødem er en kombination af Entresto og en ACE-hæmmer kontraindiceret (se pkt.
English: Entresto has not been studied in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (see sections 4.3 and 4.4).
Danish: Entresto er ikke undersøgt hos patienter med svært nedsat leverfunktion, biliær cirrhose eller cholestase (se pkt.
English: Entresto 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Danish: Entresto 49 mg/51 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171)
English: Entresto 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Danish: Entresto 97 mg/103 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171)
English: Therefore, co-administration of Entresto with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir,
Danish: Det er derfor muligt, at anvendelse af Entresto sammen med hæmmere af OATP1B1, OATP1B3 og OAT3 (fx rifampicin, ciclosporin), OAT1 (fx tenofovir, cidofovir) eller MRP2 (fx ritonavir) kan øge den systemiske eksponering af LBQ657 eller valsartan.
English: If you take more Entresto than you should
Danish: Hvis du har taget for meget Entresto
English: Entresto 24 mg/26 mg tablets sacubitril/valsartan
Danish: Entresto 24 mg/26 mg tabletter sacubitril/valsartan
English: Entresto 97 mg/103 mg tablets sacubitril/valsartan
Danish: Entresto 97 mg/103 mg tabletter sacubitril/valsartan
English: Entresto 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Danish: Entresto 24 mg/26 mg filmovertrukne tabletter Hypromellose, substitutionstype 2910 (3 mPa s) Titaniumdioxid (E171)
English: • The combination of Entresto with direct renin inhibitors such as aliskiren is not recommended (see section 4.5).
Danish: • Det frarådes at give Entresto sammen med en direkte reninhæmmer som fx aliskiren (se pkt.
English: ACE inhibitor therapy must not be started until 36 hours after the last dose of Entresto (see sections 4.2 and 4.3).
Danish: Behandling med ACE-hæmmer må ikke påbegyndes før 36 timer efter den sidste dosis Entresto (se pkt.
English: A slight increase in two foetal skeletal variations (misshapen sternebra, sternebra bipartite ossification) was observed in rabbits at an Entresto dose of
Danish: En let øgning i to føtale, skeletale variationer (misdannet sternebra, tvedelt knogledannelse af sternebra) blev observeret hos kaniner ved en dosis af Entresto på 4,9 mg sacubitril/5,1 mg valsartan/kg/dag.
English: Entresto 49 mg/51 mg tablets sacubitril/valsartan
Danish: Entresto 49 mg/51 mg tabletter sacubitril/valsartan
English: Approximate tablet dimensions 13.1 mm x 5.2 mm Entresto 97 mg/103 mg film-coated tablets are light pink oval tablets with “NVR” on one side and “L11” on the other side.
Danish: Entresto 97 mg/103 mg filmovertrukne tabletter er lyserøde ovale tabletter med ”NVR” på den ene side og ”L11” på den anden side.
English: Entresto 24 mg/26 mg film-coated tablets sacubitril/valsartan
Danish: Entresto 24 mg/26 mg filmovertrukne tabletter sacubitril/valsartan
English: Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Danish: Entresto 97 mg/103 mg filmovertrukne tabletter sacubitril/valsartan
English: Entresto 49 mg/51 mg film-coated tablets sacubitril/valsartan
Danish: Entresto 49 mg/51 mg filmovertrukne tabletter sacubitril/valsartan
English: As there is very limited clinical experience in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) (see section 5.1) Entresto should be used with caution and a starting dose of 24 mg/26 mg twice daily is recommended.
Danish: Da der er meget begrænset klinisk erfaring hos patienter med svært nedsat nyrefunktion (eGFR <30 ml/min/1,73 m2) (se pkt.
English: • Known history of angioedema related to previous ACE inhibitor or ARB therapy (see section 4.4).
Danish: • Kendt angioødem i anamnesen i forbindelse med tidligere behandling med ACE-hæmmer eller
English: Tablet core
Danish: Fuldt analysesæt
English: This will normally bring the blood calcium level down to normal levels within a week.
Danish: Dette vil sædvanligvis bringe mængden af calcium i blodet ned på et normalt niveau inden for en uge.
English: Patients should also take vitamin D and calcium supplements.
Danish: Patienterne bør desuden tage D-vitamin- og calciumtilskud.
English: This reduces bone loss.
Danish: Dette reducerer knogletabet.
English: The full EPAR for Ibandronic acid Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Ibandronsyre Accord findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ibandronic acid Accord on 19 November 2012.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Ibandronsyre Accord den 19. november 2012.
English: For the prevention of skeletal events or the treatment of hypercalcaemia in cancer patients, treatment with this medicine should only be started by a doctor who has experience in the treatment of cancer.
Danish: Til forebyggelse af knoglerelaterede hændelser eller behandling af hypercalcæmi hos kræftpatienter bør behandling med dette lægemiddel kun indledes af en læge med erfaring i kræftbehandling.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicines, Bondronat and Bonviva, and do not need to be repeated for Ibandronic acid Accord.
Danish: Der er allerede gennemført undersøgelser af fordelene og risiciene ved det aktive stof i de godkendte anvendelser med referencelægemidlerne, Bondronat og Bonviva, og det er ikke nødvendigt at gentage disse for Ibandronsyre Accord.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Ibandronic acid Accord has been shown to be comparable to Bondronat and Bonviva.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at det i overensstemmelse med EU's krav er blevet påvist, at Ibandronsyre Accord er sammenlignelig med Bondronat og Bonviva.
English: • prevent ‘skeletal events' (fractures or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone);
Danish: • forebyggelse af "knoglerelaterede hændelser" (knoglebrud eller knoglekomplikationer, der kræver behandling) hos patienter med brystkræft og knoglemetastaser (kræft, der har spredt sig til knoglerne)
English: As for every medicine, the company provided studies on the quality of Ibandronic acid Accord.
Danish: Som for alle lægemidler fremlagde virksomheden undersøgelser af kvaliteten af Ibandronsyre Accord.
English: This is a summary of the European public assessment report (EPAR) for Ibandronic acid Accord.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Ibandronsyre Accord.
English: • treat hypercalcaemia (high levels of calcium in the blood) caused by tumours.
Danish: • behandling af hypercalcæmi (øget mængde kalcium i blodet), der skyldes svulster.
English: The Agency recommended that Ibandronic acid Accord be approved for use in the EU.
Danish: Agenturet anbefalede, at Ibandronsyre Accord godkendes til anvendelse i EU.
English: There was no need for ‘bioequivalence' studies to investigate whether Ibandronic acid Accord is absorbed similarly to the reference medicines to produce the same level of the active substance in the blood.
Danish: Der var ikke behov for "bioækvivalente" undersøgelser af, om Ibandronsyre Accord absorberes på samme måde som referencelægemidlerne for at producere samme niveau af det aktive stof i blodet.
English: This is because Ibandronic acid Accord is given by infusion or injection into a vein, so the active substance is delivered straight into the bloodstream.
Danish: Dette skyldes, at Ibandronsyre Accord gives ved infusion eller injektion i en vene, så det aktive stof ledes direkte ind i blodbanen.
English: Patients with moderate or severe kidney problems should receive Ibandronic acid Accord infusions at a lower dose over an hour.
Danish: Patienter med moderate eller svære nyreproblemer skal have infusionerne med Ibandronsyre Accord i en lavere dosis i løbet af en time.
English: The reduction of bone loss helps to make bones less likely to break in cancer patients with bone metastases and in women with osteoporosis.
Danish: Reduktionen af knogletabet bidrager til at mindske sandsynligheden for knoglebrud hos kræftpatienter med knoglemetastaser og hos kvinder med osteoporose.
English: Patients with tumours can have high levels of calcium in their blood, released from the bones.
Danish: Patienter med svulster kan have en forhøjet mængde calcium i blodet, der er afgivet fra knoglerne.
English: By preventing the breakdown of bones, Ibandronic acid Accord also helps to reduce the amount of calcium released into the blood.
Danish: Ved at forebygge nedbrydning af knoglerne medvirker Ibandronsyre Accord også til at mindske den mængde calcium, der afgives til blodet.
English: Osteonecrosis of the jaw is a condition affecting the bones of the jaw, which could lead to pain, sores in the mouth or loose teeth.
Danish: Osteonekrose i kæben er en lidelse, som påvirker kæbeknoglerne, og som kan medføre smerter, mundsår eller løse tænder.
English: The company that markets Ibandronic acid Accord will provide a card to inform patients receiving Ibandronic acid Accord infusion about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they get symptoms.
Danish: Virksomheden, som markedsfører Ibandronsyre Accord, vil udarbejde et patientkort til patienter, som får Ibandronsyre Accord, med oplysninger om risikoen for osteonekrose i kæben og en instruks til dem om at kontakte deres læge, hvis de får symptomer.
English: For the treatment of osteoporosis, Ibandronic acid Accord is given as an injection into a vein once every three months.
Danish: Til behandling af osteoporose gives Ibandronsyre Accord som en injektion i en vene en gang hver tredje måned.
English: This means that Ibandronic acid Accord contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU).
Danish: Det betyder, at Ibandronsyre Accord er identisk med et "referencelægemiddel", som allerede er godkendt i Den Europæiske Union (EU).
English: What measures are being taken to ensure the safe and effective use of Ibandronic acid Accord?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Ibandronsyre Accord?
English: Ibandronic acid Accord contains the active substance ibandronic acid and is a ‘generic medicine'.
Danish: Ibandronsyre Accord indeholder det aktive stof ibandronsyre og er et "generisk lægemiddel".
English: Because Ibandronic acid Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicines'.
Danish: Da Ibandronsyre Accord er et generisk lægemiddel, anses benefit/risk-forholdet for at være det samme som for referencelægemidlerne.
English: It is not intended to provide practical advice on how to use Ibandronic acid Accord.
Danish: Det er ikke en praktisk vejledning i, hvordan Ibandronsyre Accord bør anvendes.
English: Ibandronic acid Accord is a medicine used to treat certain conditions affecting bones and blood calcium.
Danish: Ibandronsyre Accord er et lægemiddel, der anvendes til at behandle visse sygdomme, der påvirker knoglerne og blodets indhold af calcium.
English: Other information about Ibandronic acid Accord
Danish: Andre oplysninger om Ibandronsyre Accord
English: For more information about treatment with Ibandronic acid Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Ibandronsyre Accord, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: The active substance in Ibandronic acid Accord, ibandronic acid, is a bisphosphonate.
Danish: Det aktive stof i Ibandronsyre Accord, ibandronsyre, er et bisphosphonat.
English: In the prevention of skeletal events in patients with breast cancer and bone metastases, Ibandronic acid Accord is given into a vein as a 6 mg infusion lasting at least 15 minutes every three to four weeks.
Danish: Til forebyggelse af knoglerelaterede hændelser hos patienter med brystkræft og knoglemetastaser gives Ibandronsyre Accord som en 6 mg-infusion i en vene over mindst 15 minutter hver tredje til fjerde uge.
English: What are the benefits and risks of Ibandronic acid Accord?
Danish: Hvilke fordele og risici er der forbundet med Ibandronsyre Accord?
English: It stops the action of osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
Danish: Det virker hæmmende på osteoklaster, der er de celler i kroppen, som medvirker ved nedbrydningen af knoglevæv.
English: What is Ibandronic acid Accord and what is it used for?
Danish: Hvad er Ibandronsyre Accord, og hvad anvendes det til?
English: Ibandronic acid Accord concentrate for solution for infusion (drip) is used in adults to:
Danish: Ibandronsyre Accord-koncentratet til fremstilling af en infusionsvæske, opløsning, anvendes til voksne til:
English: In the treatment of hypercalcaemia caused by tumours, Ibandronic acid Accord is given into a vein as an infusion of 2 or 4 mg, depending on how severe the hypercalcaemia is.
Danish: Ved behandling af hypercalcæmi forårsaget af svulster gives Ibandronsyre Accord i en vene som en infusion på enten 2 eller 4 mg, afhængigt af hvor alvorlig hypercalcæmien er. Infusionen varer to timer.
English: Ibandronic acid Accord is available as a solution for injection (3 mg) in a pre-filled syringe and as a concentrate (2 mg and 6 mg) to be made up into a solution for infusion (drip) into a vein.
Danish: Ibandronsyre Accord fås som injektionsvæske, opløsning, (3 mg) i fyldte injektionssprøjter og som et koncentrat (2 og 6 mg), der fortyndes til en opløsning, som gives som infusion (drop) i en vene.
English: Therefore, the Agency's view was that, as for Bondronat and Bonviva, the benefit outweighs the identified risk.
Danish: Det var derfor agenturets opfattelse, at fordelene opvejer de identificerede risici som for Bondronat og Bonviva.
English: The reference medicines for Ibandronic acid Accord are Bondronat and Bonviva.
Danish: Referencelægemidlerne for Ibandronsyre Accord er Bondronat og
English: For practical information about using Ibandronic acid Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Danish: Hvis du ønsker praktisk vejledning om anvendelsen af Ibandronsyre Accord, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
English: Ibandronic acid Accord ibandronic acid
Danish: Ibandronsyre Accord ibandronsyre
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ibandronic acid Accord have also been included in the summary of product characteristics and the package leaflet.
Danish: Der er desuden anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Ibandronsyre Accord.
English: Why is Ibandronic acid Accord approved?
Danish: Hvorfor blev Ibandronsyre Accord godkendt?
English: Ibandronic acid Accord solution for injection is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of developing bone fractures (breaks).
Danish: Ibandronsyre Accord, injektionsvæske, opløsning, anvendes til behandling af osteoporose (knogleskørhed) hos kvinder efter overgangsalderen, som har forhøjet risiko for knoglebrud.
English: How has Ibandronic acid Accord been studied?
Danish: Hvordan blev Ibandronsyre Accord undersøgt?
English: How is Ibandronic acid Accord used?
Danish: Hvordan anvendes Ibandronsyre Accord?